Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

36.26USD
23 Feb 2018
Change (% chg)

$0.52 (+1.45%)
Prev Close
$35.74
Open
$35.93
Day's High
$36.30
Day's Low
$35.83
Volume
17,020,895
Avg. Vol
19,602,031
52-wk High
$39.43
52-wk Low
$31.67

Latest Key Developments (Source: Significant Developments)

Pfizer Receives Positive CHMP Opinion For Two Hematology Medicines
Friday, 23 Feb 2018 09:00am EST 

Feb 23 (Reuters) - Pfizer Inc ::PFIZER RECEIVES POSITIVE CHMP OPINION FOR TWO HEMATOLOGY MEDICINES, MYLOTARG™ AND BOSULIF®.PFIZER INC - CHMP OF EMA HAS ADOPTED POSITIVE OPINIONS RECOMMENDING THAT MYLOTARG, BOSULIF BE GRANTED MARKETING AUTHORIZATIONS IN EU.  Full Article

Pfizer Says CHMP Of EMA Recommended Against Expanding Use Of Sutent
Friday, 23 Feb 2018 08:30am EST 

Feb 23 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES UPDATE ON EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR SUTENT® (SUNITINIB) IN ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA.PFIZER - CHMP OF EMA RECOMMENDED AGAINST EXPANDING USE OF SUTENT.  Full Article

Albert Bourla Elected To Pfizer’S Board Of Directors
Friday, 23 Feb 2018 08:00am EST 

Feb 23 (Reuters) - Pfizer Inc ::ALBERT BOURLA ELECTED TO PFIZER’S BOARD OF DIRECTORS.PFIZER INC - ‍BOURLA IS CURRENTLY COO OF PFIZER​.  Full Article

EMA Recommends Against Approval Of Puma Biotechnology's Breast Cancer Drug Neratinib‍​
Friday, 23 Feb 2018 06:30am EST 

Feb 23 (Reuters) - EU Medicines Agency::EU MEDICINES AGENCY RECOMMENDATIONS FOR FEBRUARY 2018.EU MEDICINES AGENCY RECOMMENDATIONS FOR FEBRUARY 2018 BREAST CANCER DRUG NERATINIB.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF PFIZER'S MYLOTARG FOR TREATMENT OF ACUTE MYELOID LEUKAEMIA‍​‍​‍​.  Full Article

Spark Therapeutics Enters Into A Spk-9001 Manufacture And Supply Agreement With Pfizer
Tuesday, 20 Feb 2018 08:22am EST 

Feb 20 (Reuters) - Spark Therapeutics Inc ::SPARK THERAPEUTICS INC - ON FEB 16, CO ENTERED INTO A SPK-9001 MANUFACTURE AND SUPPLY AGREEMENT WITH PFIZER - SEC FILING.SPARK THERAPEUTICS SAYS UNDER AGREEMENT, PFIZER WILL PAY CO $7 MILLION UPON EXECUTION OF AGREEMENT - SEC FILING.SPARK THERAPEUTICS INC - THE AGREEMENT IS TO MANUFACTURE AND DELIVER TO PFIZER SPARK-9001 BULK DRUG SUBSTANCE.SPARK THERAPEUTICS INC - UNDER AGREEMENT, PFIZER MAY MAKE A SECOND PAYMENT TO CO OF UP TO $7 MILLION.SPARK THERAPEUTICS INC - CO WILL BEGIN SPARK-9001 BULK DRUG SUBSTANCE MANUFACTURE IN THE FIRST QUARTER OF 2018.  Full Article

Reckitt CEO bullish on consumer health, no comment on Pfizer
Monday, 19 Feb 2018 02:38am EST 

Feb 19 (Reuters) - Reckitt Benckiser Group Plc ::RECKITT BENCKISER CEO SAYS NO COMMENT ON PFIZER CONSUMER HEALTH AUCTION.RECKITT BENCKISER CEO SAYS ACQUISITIONS MUST BE STRATEGICALLY COMPELLING, RB MUST BE A BETTER OWNER, AND MUST DRIVE VALUE FOR SHAREHOLDERS.RECKITT BENCKISER CEO SAYS CONFIDENT ABOUT GROWTH OF CONSUMER HEALTH CATEGORY IN LONG TERM.  Full Article

Pfizer Receives Breakthrough Therapy Designation From FDA For Atopic Dermatitis Treatment, PF-04965842
Wednesday, 14 Feb 2018 08:30am EST 

Feb 14 (Reuters) - Pfizer Inc ::PFIZER RECEIVES BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR PF-04965842, AN ORAL JAK1 INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS.  Full Article

Pfizer says U.S., EU And Japan Health Authorities Accept Lorlatinib For Review
Monday, 12 Feb 2018 08:00am EST 

Feb 12 (Reuters) - Pfizer Inc ::U.S., EU AND JAPAN HEALTH AUTHORITIES ACCEPT REGULATORY SUBMISSIONS FOR REVIEW OF PFIZER’S THIRD-GENERATION ALK INHIBITOR LORLATINIB.PFIZER INC - U.S. NEW DRUG APPLICATION FOR LORLATINIB GRANTED FDA PRIORITY REVIEW.  Full Article

GSK's ViiV Healthcare Says Filed Patent Infringement Litigation Against Gilead Sciences
Thursday, 8 Feb 2018 02:00am EST 

Feb 8 (Reuters) - Glaxosmithkline Plc ::VIIV FILES PATENT INFRINGEMENT LITIGATION.GLAXOSMITHKLINE PLC - VIIV ‍ANNOUNCED IT FILED PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR IN UNITED STATES AND CANADA​.  Full Article

ViiV Healthcare files patent infringement litigation against Gilead Sciences
Wednesday, 7 Feb 2018 04:15pm EST 

Feb 7 (Reuters) - :VIIV HEALTHCARE FILES PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR.VIIV HEALTHCARE - FILED PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR IN THE UNITED STATES AND CANADA.VIIV HEALTHCARE - WILL SEEK TO PROVE THAT GILEAD'S TRIPLE COMBINATION HIV DRUG INFRINGES CO'S PATENT COVERING DOLUTEGRAVIR AND MANY OTHER COMPOUNDS.VIIV HEALTHCARE - VIIV HEALTHCARE WILL SEEK FINANCIAL REDRESS FOR PATENT INFRINGEMENT.  Full Article

BRIEF-Pfizer Receives Positive CHMP Opinion For Two Hematology Medicines

* PFIZER RECEIVES POSITIVE CHMP OPINION FOR TWO HEMATOLOGY MEDICINES, MYLOTARG™ AND BOSULIF®